JP2019512493A - 移植片対宿主病の処置または予防の方法 - Google Patents

移植片対宿主病の処置または予防の方法 Download PDF

Info

Publication number
JP2019512493A
JP2019512493A JP2018548192A JP2018548192A JP2019512493A JP 2019512493 A JP2019512493 A JP 2019512493A JP 2018548192 A JP2018548192 A JP 2018548192A JP 2018548192 A JP2018548192 A JP 2018548192A JP 2019512493 A JP2019512493 A JP 2019512493A
Authority
JP
Japan
Prior art keywords
antibody
seq
humanized antibody
gvhd
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018548192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512493A5 (cg-RX-API-DMAC7.html
Inventor
エイ. サックス,ジェシカ
エイ. サックス,ジェシカ
イー. フォード,ジョン
イー. フォード,ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2019512493A publication Critical patent/JP2019512493A/ja
Publication of JP2019512493A5 publication Critical patent/JP2019512493A5/ja
Priority to JP2022092849A priority Critical patent/JP2022137024A/ja
Priority to JP2025065073A priority patent/JP2025118642A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018548192A 2016-03-14 2017-03-13 移植片対宿主病の処置または予防の方法 Withdrawn JP2019512493A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022092849A JP2022137024A (ja) 2016-03-14 2022-06-08 移植片対宿主病の処置または予防の方法
JP2025065073A JP2025118642A (ja) 2016-03-14 2025-04-10 移植片対宿主病の処置または予防の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14
US62/307,896 2016-03-14
US201662420825P 2016-11-11 2016-11-11
US62/420,825 2016-11-11
PCT/US2017/022067 WO2017160700A1 (en) 2016-03-14 2017-03-13 Methods of treating or preventing graft versus host disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022092849A Division JP2022137024A (ja) 2016-03-14 2022-06-08 移植片対宿主病の処置または予防の方法

Publications (2)

Publication Number Publication Date
JP2019512493A true JP2019512493A (ja) 2019-05-16
JP2019512493A5 JP2019512493A5 (cg-RX-API-DMAC7.html) 2020-05-14

Family

ID=58455657

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018548192A Withdrawn JP2019512493A (ja) 2016-03-14 2017-03-13 移植片対宿主病の処置または予防の方法
JP2022092849A Pending JP2022137024A (ja) 2016-03-14 2022-06-08 移植片対宿主病の処置または予防の方法
JP2025065073A Pending JP2025118642A (ja) 2016-03-14 2025-04-10 移植片対宿主病の処置または予防の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022092849A Pending JP2022137024A (ja) 2016-03-14 2022-06-08 移植片対宿主病の処置または予防の方法
JP2025065073A Pending JP2025118642A (ja) 2016-03-14 2025-04-10 移植片対宿主病の処置または予防の方法

Country Status (12)

Country Link
US (1) US20190077868A1 (cg-RX-API-DMAC7.html)
EP (1) EP3430053A1 (cg-RX-API-DMAC7.html)
JP (3) JP2019512493A (cg-RX-API-DMAC7.html)
KR (2) KR102667332B1 (cg-RX-API-DMAC7.html)
CN (2) CN109153721A (cg-RX-API-DMAC7.html)
AU (2) AU2017234010B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018068625A2 (cg-RX-API-DMAC7.html)
CA (1) CA3017758A1 (cg-RX-API-DMAC7.html)
IL (1) IL261767B1 (cg-RX-API-DMAC7.html)
MA (1) MA43755A (cg-RX-API-DMAC7.html)
MX (2) MX2018011025A (cg-RX-API-DMAC7.html)
WO (1) WO2017160700A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3430052A2 (en) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
IL270201B2 (en) * 2017-04-28 2026-05-01 Millennium Pharm Inc A method for treating childhood disorders
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル. モリソン,シェリー ドメイン‐変性不変部を有する抗体
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
ZA200803016B (en) * 2005-09-29 2009-10-28 Elan Pharmaceuticals Inc Wyeth Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
DK2637672T3 (en) * 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
JP7105188B2 (ja) * 2015-08-25 2022-07-22 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン 幹細胞移植方法
EP3430052A2 (en) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"EXPRESSION OF α4β7 INTEGRIN ON MEMORY CD8+ T-CELLS IS INCREASED IN PATIENTS AT PRESENTATION OF ACU", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 18, no. 2, JPN6021013984, 2011, pages 221 - 49, ISSN: 0004849299 *
"Targeting Integrin a4b7-Expressing T-Cells in Steroid Refractory Intestinal GvHD", BLOOD, vol. 126, no. 23, JPN6021013982, 2015, pages 3137, ISSN: 0004849298 *
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 14, no. 1, JPN6022034480, 2008, pages 75 - 87, ISSN: 0004849302 *
日本輸血細胞治療学会誌, vol. 56, no. 3, JPN6022034479, 2010, pages 359 - 364, ISSN: 0004849301 *
最新医学, vol. 63, no. 8, JPN6022034478, 2008, pages 1635 - 1640, ISSN: 0004849300 *

Also Published As

Publication number Publication date
KR20180117195A (ko) 2018-10-26
US20190077868A1 (en) 2019-03-14
MX2024008740A (es) 2024-07-23
WO2017160700A1 (en) 2017-09-21
JP2025118642A (ja) 2025-08-13
MA43755A (fr) 2018-11-28
AU2017234010B2 (en) 2024-06-13
MX2018011025A (es) 2019-01-10
BR112018068625A2 (pt) 2019-07-30
KR102667332B1 (ko) 2024-05-20
AU2017234010A1 (en) 2018-09-27
KR20240074903A (ko) 2024-05-28
AU2024203289A1 (en) 2024-08-01
CN109153721A (zh) 2019-01-04
CA3017758A1 (en) 2017-09-21
IL261767B1 (en) 2026-07-01
KR102830639B1 (ko) 2025-07-07
EP3430053A1 (en) 2019-01-23
IL261767A (en) 2018-10-31
JP2022137024A (ja) 2022-09-21
CN117298268A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
JP7474287B2 (ja) 炎症性腸疾患の治療を目的とする三剤併用療法
JP2025118642A (ja) 移植片対宿主病の処置または予防の方法
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
EP3063173B1 (en) Specific anti-cd38 antibodies for treating human cancers
JP2022163078A (ja) 移植片対宿主病予防の方法
JP2023551559A (ja) 抗cd19併用療法
JP7497159B2 (ja) 慢性回腸嚢炎の治療のための方法
US20250122289A1 (en) Methods of treating or preventing graft versus host disease
US20250101097A1 (en) Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
JP2022529970A (ja) 抗psma/cd3抗体で腎癌を治療する方法
US20260042835A1 (en) Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies
EA041816B1 (ru) Способ профилактики болезни "трансплантат против хозяина"

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190611

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220608

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220608

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220621

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220722

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220726

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220819

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240626

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240730